The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 86 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 0.6 mo · strongest signal: Equity line (Aug 27, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (atm program, equity line, warrant inducement). Base case is a discounted raise; the question is when, not if.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
On August 14, 2026, Worksport disclosed receipt of a Nasdaq minimum bid price deficiency notice (8-K Item 3.01), triggered by 30 consecutive trading days below $1.00, giving the company until February 9, 2027 to regain compliance. The company has approximately 0.6 months of cash runway based on $1.16 million liquidity as of June 30, 2026 and an annualized burn rate of $23.7 million. Concurrently, Worksport filed an amended ATM prospectus supplement on August 7, 2026 for up to $493,000 of common stock sales under its September 2022 Sales Agreement with H.C. Wainwright, and disclosed an equity line financing arrangement and warrant inducement on August 27, 2026 (8-K Item 1.01/3.02).
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 80 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 27, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-27 filing | 52 |
| Aug 27, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (8-K) filed 2026-08-27 filing | 40 |
| Aug 27, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-08-27 filing | 40 |
| Aug 27, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-08-27 filing | 34 |
| Aug 27, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-27 (accepted 16:17 ET) filing | 32 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~0.6 months runway: liquidity $1,160,158 as of 2026-06-30, burn $23,678,655/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 45 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $1,160,158 vs current liabilities $3,929,260 filing | 22 |
AUID authID Inc. · SOBR SOBR Safe, Inc. · SDST Stardust Power Inc. · ADIL ADIAL PHARMACEUTICALS, INC. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · screener →